Eur Rev Med Pharmacol Sci 2020; 24 (18): 9541-9548
DOI: 10.26355/eurrev_202009_23039

Abnormal expression of Rap2A as a prognostic marker for human breast cancer

J.-Q. Liu, L.-P. Zhao, S.-X. Liu, W. Sun, H.-Y. Qi

Department of Galactophore, Linyi Cancer Hospital, Linyi, China. qihaiyan008@163.com

 


OBJECTIVE: The aim of this study was to explore the expression of GTPase protein Ras-related protein Rap-2a (Rap2A) in breast cancer (BC). Furthermore, the associations of Rap2A with clinicopathological parameters of BC patients were investigated.

PATIENTS AND METHODS: quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was used to examine Rap2A expression in BC tissues and cells. The association between Rap2A expression and clinicopathological characteristics was analyzed by Chi-square test. Low expression of Rap2A in BC cells was conducted by transfection of small interfering RNA (siRNA). Subsequently, colony formation assay and transwell assay were used to detect the proliferation and invasion abilities of BC cells, respectively.

RESULTS: Rap2A was highly expressed in both BC tissues and cells (p<0.05). Further analysis showed that tumor size, clinical stage, and distant metastasis were correlated with Rap2A expression (p<0.05). Besides, inhibition of Rap2A significantly decreased the proliferation and invasion abilities of BC cells (p<0.05).

CONCLUSIONS: Rap2A acted as a promotor in the development of BC. Our findings suggested that Rap2A might be a new potential therapeutic target marker for BC treatment.

Free PDF Download

To cite this article

J.-Q. Liu, L.-P. Zhao, S.-X. Liu, W. Sun, H.-Y. Qi
Abnormal expression of Rap2A as a prognostic marker for human breast cancer

Eur Rev Med Pharmacol Sci
Year: 2020
Vol. 24 - N. 18
Pages: 9541-9548
DOI: 10.26355/eurrev_202009_23039